SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Biotech success, 2002
An SI Board Since January 2002
Posts SubjectMarks Bans
117 19 0
Emcee:  Miljenko Zuanic Type:  Unmoderated
Introduction Compact
To counter-balance tread *biotech-failure, 2002*
Subject 52275

This tread is to record significant achievement and success from bios.

Please no crap-shot.

News that may qualify should report:
1. Scientific achievement which will *shake* sector
2. Significant positive PIIb or PIII results
3. NDA (ANDA) submission and approval
4. Large collaboration-partnership
5. Unexpected strong market penetration
6. ...

Miljenko
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
117Velcade approval - Message 18941041nigel bates-5/13/2003
116BioMarin, Genzyme Announce FDA Marketing Approval for Aldurazyme NOVATO, Calif.nigel bates-5/1/2003
115re: AMEX: IMA @ $16 (Inverness Medical Innnovation) not a typical biotech compaCrossy-1/28/2003
114seems the fda is realy changing its pace Welcome, dalroi [Sign Out] Money Mandalroi-1/1/2003
113Have no idea was Eyetech deal mentioned anywhere at SI, but bios (we) have two nMiljenko Zuanic-12/20/2002
112I think the Diversa / Syngenta research deal is just about big enough to make thnigel bates-12/4/2002
111Certainly a success for Antisoma - Roche to acquire rights to promising portfolnigel bates-11/18/2002
110Lots of talk, but very little data presented! Press Release Source: The MedicinMiljenko Zuanic-11/17/2002
109Angiomax success. (sorry, couldn't get format right.) biz.yahoo.comkeokalani'nui-11/17/2002
108Press Release Source: Eli Lilly REPEAT/Cialis -- tadalafil -- Approved by EuroMiljenko Zuanic-11/14/2002
107NBIX Trial biz.yahoo.comElmer-11/14/2002
106Nice! Press Release Source: GenVec, Inc. Gene Therapy in Combination With RadMiljenko Zuanic-11/8/2002
105Old: <<The proximal VTE/PE rate was 3.3 percent for ximelagatran and 5.0 Miljenko Zuanic-10/29/2002
104<Exanta> Those are quite some p values! This is particularly instructiveBiomaven-10/29/2002
103Press Release Source: AstraZeneca LP AstraZeneca's Investigational Oral AnMiljenko Zuanic-10/28/2002
102SOUTH SAN FRANCISCO, Calif., and LONDON, Oct. 28 /PRNewswire-FirstCall/ -- Exelinigel bates-10/28/2002
101Vertex Pharmaceuticals Provides Update on GW433908 (908; VX-175) Clinical Develokeokalani'nui-10/23/2002
100CV THERAPEUTICS UPDATES PROGRESS WITH TECADENOSON PALO ALTO, CALIF., OCTOBER 22Biomaven-10/23/2002
99Last Wednesday, favorable report from Investrend has had a positive effect shortnumbrcrunchr-10/22/2002
98Thanks to Ian. 77 Per Cent of Multiple Myeloma Patients Showed Reduction or StaMiljenko Zuanic-10/20/2002
97One bright spot for sector. Reuters Company News IDEC says net income to rise oMiljenko Zuanic-10/9/2002
96Press Release Source: AstraZeneca Pharmaceuticals FDA Advisory Committee VotesMiljenko Zuanic-9/24/2002
95Another nice milestone. Message 18017801Miljenko Zuanic-9/21/2002
94WE, Regardless that they split profit (not a sale numbers), I will bet that LLYMiljenko Zuanic-9/21/2002
93You know, I'm not sure I would peg my reward for a really super drug so greakeokalani'nui-9/20/2002
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News